AUSTIN, Texas, April 11, 2024 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting the use of the Prospera Kidney donor-derived cfDNA (dd-cfDNA) test as a leading indicator of kidney transplant rejection. The published manuscript can be found here.
The Gallatin County Commission approves important funding for a resident-owned-community in Belgrade.The $650,000 revolving loan puts the Gallatin Valley's firs
Three Prospera Credit Union ATMs were compromised by skimming devices during a week-long scam, leading to a number of unauthorized customer transactions.